{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:12:39Z","timestamp":1773069159346,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,18]]},"DOI":"10.7759\/cureus.62601","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T13:02:40Z","timestamp":1718715760000},"source":"Crossref","is-referenced-by-count":1,"title":["Cooccurrence of Myasthenia Gravis and Epilepsy: A Case Report"],"prefix":"10.7759","author":[{"given":"Intissar","family":"Barbouch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouchra","family":"Ennar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoutar","family":"Chhita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yassine","family":"Mebrouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus NE","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015, 14:1023-36.","journal-title":"Lancet Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir MK","year":"2018","unstructured":"Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018, 36:253-60. 10.1016\/j.ncl.2018.01.002","journal-title":"Neurol Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.188","article-title":"Population-level evidence for an autoimmune etiology of epilepsy","volume":"71","author":"Ong MS","year":"2014","unstructured":"Ong MS, Kohane IS, Cai T, Gorman MP, Mandl KD. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol. 2014, 71:569-74. 10.1001\/jamaneurol.2014.188","journal-title":"JAMA Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-510x(99)00205-1","article-title":"Does myasthenia gravis affect the brain?","volume":"30","author":"Keesey JC","year":"1999","unstructured":"Keesey JC. Does myasthenia gravis affect the brain?. J Neurol Sci. 1999, 30:77-89. 10.1016\/s0022-510x(99)00205-1","journal-title":"J Neurol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: an update","volume":"10","author":"Sheikh S","year":"2021","unstructured":"Sheikh S, Alvi U, Soliven B, Rezania K. Drugs that induce or cause deterioration of myasthenia gravis: an update. J Clin Med. 2021, 10:1537. 10.3390\/jcm10071537","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes EG","year":"2010","unstructured":"Hughes EG, Peng X, Gleichman AJ, et al.. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010, 30:5866-75. 10.1523\/JNEUROSCI.0167-10.2010","journal-title":"J Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-31","article-title":"In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction","volume":"5","author":"Manto M","year":"2010","unstructured":"Manto M, Dalmau J, Didelot A, Rogemond V, Honnorat J. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis. 2010, 5:31. 10.1186\/1750-1172-5-31","journal-title":"Orphanet J Rare Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-43257","article-title":"Antibody positive myasthenia gravis following treatment with carbamazepine--a chance association?","volume":"34","author":"Kurian MA","year":"2003","unstructured":"Kurian MA, King MD. Antibody positive myasthenia gravis following treatment with carbamazepine--a chance association?. Neuropediatrics. 2003, 34:276-7. 10.1055\/s-2003-43257","journal-title":"Neuropediatrics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/262797-cooccurrence-of-myasthenia-gravis-and-epilepsy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T13:02:43Z","timestamp":1718715763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/262797-cooccurrence-of-myasthenia-gravis-and-epilepsy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.62601","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,18]]}}}